Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC. Demeter LM, et al. Among authors: resnick l. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):135-44. doi: 10.1097/00042560-199810010-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9768622 Clinical Trial.
A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.
Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-Reese J, Dearmas L, Chidekel J, McCann M, Myers M. Fischl MA, et al. Among authors: resnick l. J Acquir Immune Defic Syndr (1988). 1991;4(1):1-10. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1670585 Clinical Trial.
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C, et al. Reichman RC, et al. Among authors: resnick l. J Infect Dis. 1995 Feb;171(2):297-304. doi: 10.1093/infdis/171.2.297. J Infect Dis. 1995. PMID: 7531207 Clinical Trial.
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D. Morse GD, et al. Among authors: resnick l. Antiviral Res. 2000 Jan;45(1):47-58. doi: 10.1016/s0166-3542(99)00073-x. Antiviral Res. 2000. PMID: 10774589 Clinical Trial.
HIV-1 propagates in human neuroblastoma cells.
Shapshak P, Sun NC, Resnick L, Thornthwaite JT, Schiller P, Yoshioka M, Svenningsson A, Tourtellotte WW, Imagawa DT. Shapshak P, et al. Among authors: resnick l. J Acquir Immune Defic Syndr (1988). 1991;4(3):228-37. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1704060
291 results